Physician profile
Giora Weisz
NPI 1306891767
$88,204.80
in general payments reported to CMS, 2019-2025
26 companies · $468 in 2025
The $468 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $42K · 2021: $683 · 2022: $3,197 · 2023: $5,652 · 2024: $4,540 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,359 · Food and Beverage: $2,572 · Travel and Lodging: $1,729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,358.65 |
| Food and Beverage | $2,572.24 |
| Travel and Lodging | $1,729.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $41,087.21 | 2019-2020 | |
| Corindus INC. | $20,231.21 | 2019 | |
| Philips North America LLC | $6,288.97 | 2019 | |
| Boston Scientific Corporation | $5,679.46 | 2019-2025 | Avvigo Guidance System, Watchman Flx, General - Vascular Access |
| Magenta Medical INC | $5,000.00 | 2023-2024 | |
| Cardiovascular Systems INC. | $3,218.60 | 2019-2021 | |
| Abbott Laboratories | $3,097.47 | 2019-2025 | Ultreon, Thoratec Heartmate 3 Lvas Implant Kit, Jot Dx |
| Medtronic, INC. | $902.18 | 2021-2024 | Abre, Onyx Frontier, Micra |
| Abiomed | $659.26 | 2019-2025 | Impella |
| Ancora Heart, INC. | $610.00 | 2019 | |
| Biotronik INC. | $251.66 | 2022 | |
| Heartflow, INC. | $196.46 | 2025 | |
| Edwards Lifesciences Corporation | $192.76 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.67 | 2021-2024 | Jardiance |
| Genzyme Corporation | $125.00 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $110.00 | 2019 | |
| Vifor Pharma, INC. | $107.00 | 2024 | Veltassa |
| Baylis Medical Company INC | $85.79 | 2021 | |
| Atricure, INC. | $77.59 | 2023 | |
| Medtronic Vascular, INC. | $36.31 | 2019 | |
| Terumo Medical Corporation | $27.37 | 2019 | |
| Impulse Dynamics (USA) INC. | $23.23 | 2023 | Optimizer |
| Novartis Pharmaceuticals Corporation | $21.65 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $14.99 | 2023 | Farxiga |
| Penumbra, INC. | $6.96 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Giora Weisz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.